

Longitudinal study on the epidemiology and management of auto immune thrombocytopenia in Alger (AITP registry)

First published: 08/08/2017

Last updated: 10/08/2017

Study

Planned

Administrative details

EU PAS number

EUPAS20416

Study ID

20479

DARWIN EU® study

No

Study countries

 American Samoa

Study description

epidemiological, national, prospective, longitudinal study about the management of patients with auto-immune thrombocytopenia followed up by hematologists in the public sector in ALGERIA The mains objectives is assessing the incidence and prevalence of the ITP IN Algeria

Study status

Planned

Research institutions and networks

Institutions

Clinica group CRO

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

MOHAMED AMINE BEKADJA mabekadja@yahoo.fr

Study contact

mabekadja@yahoo.fr

Primary lead investigator

MOHAMED AMINE BEKADJA

Study timelines

Date when funding contract was signed

Planned: 04/04/2017

Study start date

Planned: 04/05/2017

Data analysis start date

Planned: 04/05/2018

Date of final study report

Planned: 04/11/2019

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

AMGEN Algeria

Study protocol

[Protocol_AITP Algerian Registry_translated_v0 5_22Feb2017 F.pdf \(1.08 MB\)](#)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Main study objective:

EIDEMIOLOGICAL ASSESSING INCIDENCE AND PREVALENCE OF ITP

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Observational study

Population studied

Age groups

- Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Estimated number of subjects

3000

Study design details

Outcomes

ASSESS INCIDENCE BY AGE (16 YEARS AND OVER), GENDER, DIAGNOSIS STAGE, REGION OF AITP DIAGNOSED, PREVALENCE OF AITP DIAGNOSED AND DETERMINE THE CLINICAL EVOLUTION OF AITP AND DESCRIBE THE TREATMENT STRATEGIES

Data analysis plan

THE DAT WILL BE PROCESSED ANONYMOUSLY AND CONFIDENTIALLY. STATISTICAL ANALYSIS WILL BE PERFORMED USING SAS SOFTWARE

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Conflicts of interest of investigators

[FDF_Pr bekadja_site 05_EHU oRAN \(002\).pdf](#) (352.09 KB)

Data sources

Data sources (types)

[Disease registry](#)

[Other](#)

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No